Salivary, plasma metanephrines and anxiety levels in pheochromocytomas - STRESS

niversitair Medisch Centrum Groningen0 个研究点目标入组 315 人开始时间: 待定最近更新: 2024年6月11日

适应症

试验速览

暂无简介。

•Age > 18 years
•Group I: Patients with a PCC, or sPGL :
•1. elevated plasma and/or urinary (nor)metanephrines
•2. localization of a PCC or sPGL by anatomical (MRI/CT) and functional imaging (123I-metaiodobenzylguanidin (MIBG) scintigraphy or 18F-dihydrophenylalanine (DOPA) positron emission tomography (PET) or 18F-fluorodopamine PET.
•Group II: Germline mutation carriers
•1. plasma metanephrines in the normal reference range
•Group III: Healthy subjects
•1. normotensive.
•2. no documented cardiovascular history (including: hypertension, diabetes, coronary artery disease, peripheral vascular disease),

•1. Age < 18 years
•2. The need to use medication known to influence plasma metanephrines concentration: tricyclic antidepressants, phenoxybenzamine, MAO-inhibitors, sympathomimetics, cocaine, methyldopa
•3. Patient who are operated on (after inclusion) and histology shows no PCC or sPGL
•4. Patients, mutation carriers and healthy subjects who are not able to read and understand the Dutch language are not eligble for filling out the anxiety questionnair
•5. Patient,mutation carriers and healthy subjects with severe psychiatric co-morbidity (i.e. acute suicidal ideations or behaviour, recently experienced psychosis, diagnosis of schizophrenia, bipolar disorder, drug abuse or substance dependence, serious cognitive or neurological problems) are not eligible for filling out the anxiety questionnaire.

发起方